Sriram Ryali

Finanzdirektor/CFO bei CODEXIS, INC.

Vermögen: 172 939 $ am 30.04.2024

43 Jahre

Health Technology

Consumer Services

Process Industries

Aktive Positionen von Sriram Ryali

Unternehmen	Position	Beginn	Ende
CODEXIS, INC.	Comptroller/Controller/Auditor	23.01.2023	-
CODEXIS, INC.	Finanzdirektor/CFO	23.01.2023	-

Unternehmen	Position	Beginn	Ende
EIGER BIOPHARMACEUTICALS, INC.	Finanzdirektor/CFO	03.12.2018	20.01.2023
	Investor Relations Kontakt	03.12.2018	20.01.2023
	Public Communications Contact	03.12.2018	20.01.2023
AIMMUNE THERAPEUTICS, INC.	Corporate Officer/Principal	01.12.2017	01.12.2018
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Technik-/Wissenschafts-/F&E-Leiter	01.01.2013	01.01.2015
	Corporate Officer/Principal	01.01.2011	01.01.2015
JAZZ PHARMACEUTICALS PLC	Corporate Officer/Principal	01.01.2015	-

University of California, Los Angeles	Undergraduate Degree
UCLA Anderson School of Management	Masters Business Admin

International

Vereinigte Staaten	7
Irland	2

Operativ

Corporate Officer/Principal	3
Director of Finance/CFO	2
Investor Relations Contact	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	3
CODEXIS, INC.	Process Industries
JAZZ PHARMACEUTICALS PLC	Health Technology
EIGER BIOPHARMACEUTICALS, INC.	Health Technology

Private Unternehmen	2
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Health Technology
Aimmune Therapeutics, Inc. Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.	Health Technology

Private Unternehmen

Health Technology